AAAAAA

   
Results: 1-10 |
Results: 10
Leflunomide: an immunomodulatory drug for the treatment of rheumatoid arthritis and other autoimmune diseases
Authors: Herrmann, ML Schleyerbach, R Kirschbaum, BJ
Citation: Ml. Herrmann et al., Leflunomide: an immunomodulatory drug for the treatment of rheumatoid arthritis and other autoimmune diseases, IMMUNOPHARM, 47(2-3), 2000, pp. 273-289
Robert Bartlett, 1947-1998 - Obituary
Authors: Schleyerbach, R
Citation: R. Schleyerbach, Robert Bartlett, 1947-1998 - Obituary, INFLAMM RES, 48(6), 1999, pp. 289-290
In vivo lymphoproliferation in the popliteal lymph node (PLN) assay can beinhibited by leflunomide's active metabolite A77 1726
Authors: Schorlemmer, HU Kurrle, R Schleyerbach, R Bartlett, RR
Citation: Hu. Schorlemmer et al., In vivo lymphoproliferation in the popliteal lymph node (PLN) assay can beinhibited by leflunomide's active metabolite A77 1726, INFLAMM RES, 48, 1999, pp. S111-S112
Disease-modifying activity of malononitrilamides, derivatives of leflunomide's active metabolite, on models of rheumatoid arthritis
Authors: Schorlemmer, HU Kurrle, R Schleyerbach, R Bartlett, RR
Citation: Hu. Schorlemmer et al., Disease-modifying activity of malononitrilamides, derivatives of leflunomide's active metabolite, on models of rheumatoid arthritis, INFLAMM RES, 48, 1999, pp. S113-S114
Generation of O-2(-) radicals in macrophages can be inhibited in vitro andin vivo by derivatives of leflunomide's primary metabolite
Authors: Schorlemmer, HU Kurrle, R Schleyerbach, R Bartlett, RR
Citation: Hu. Schorlemmer et al., Generation of O-2(-) radicals in macrophages can be inhibited in vitro andin vivo by derivatives of leflunomide's primary metabolite, INFLAMM RES, 48, 1999, pp. S117-S118
Derivatives of leflunomide's active metabolite A77-1726, the malononitrilamides (MNAs), prevent the development of experimental arthritis
Authors: Schorlemmer, HU Schleyerbach, R
Citation: Hu. Schorlemmer et R. Schleyerbach, Derivatives of leflunomide's active metabolite A77-1726, the malononitrilamides (MNAs), prevent the development of experimental arthritis, INT J IMM T, 14(4), 1998, pp. 177-184
De novo pyrimidine biosynthesis in Jurkat T-cells is inhibited by leflunomide's primary metabolite A77-1726 at the level of dihydroorotate-dehydrogenase (DHODH)
Authors: Schorlemmer, HU Milbert, U Haun, G Wunschel, M Zeitter, D Schleyerbach, R
Citation: Hu. Schorlemmer et al., De novo pyrimidine biosynthesis in Jurkat T-cells is inhibited by leflunomide's primary metabolite A77-1726 at the level of dihydroorotate-dehydrogenase (DHODH), INT J IMM T, 14(4), 1998, pp. 193-204
A77-1726, leflunomide's active metabolite, inhibits in vivo lymphoproliferation in the popliteal lymph node assay
Authors: Schorlemmer, HU Kurrle, R Schleyerbach, R
Citation: Hu. Schorlemmer et al., A77-1726, leflunomide's active metabolite, inhibits in vivo lymphoproliferation in the popliteal lymph node assay, INT J IMM T, 14(4), 1998, pp. 205-211
Leflunomide's active metabolite A77-1726 and its derivatives, the malononitrilamides, inhibit the generation of oxygen radicals in mononuclear phagocytes
Authors: Schorlemmer, HU Kurrle, R Schleyerbach, R
Citation: Hu. Schorlemmer et al., Leflunomide's active metabolite A77-1726 and its derivatives, the malononitrilamides, inhibit the generation of oxygen radicals in mononuclear phagocytes, INT J IMM T, 14(4), 1998, pp. 213-222
Immunomodulatory activity of malononitrilamides, derivatives of leflunomide's primary metabolite, on models of experimental rheumatoid arthritis
Authors: Schorlemmer, HU Bartlett, RR Schleyerbach, R
Citation: Hu. Schorlemmer et al., Immunomodulatory activity of malononitrilamides, derivatives of leflunomide's primary metabolite, on models of experimental rheumatoid arthritis, TRANSPLAN P, 30(8), 1998, pp. 4137-4139
Risultati: 1-10 |